Nilam S. Mangalmurti

Nilam S. Mangalmurti

Auto-generated profile, based on publicly available information

Nilam S. Mangalmurti

Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
LKLeticia Kuri-Cervantes
Leticia Kuri-Cervantes
MPMaria Betina Pampena
Maria Betina Pampena
WMWenzhao Meng
Wenzhao Meng
ARAaron M. Rosenfeld
Aaron M. Rosenfeld
CICaroline A. G. Ittner
Caroline A. G. Ittner
MBMichael R. Betts
Michael R. Betts
Profound plasmablast expansion, innate cell modulation, and T cell activation are defining features of severe COVID-19.

1 February 2022 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
JLJanet S. Lee
Janet S. Lee
JBJulie A. Bastarache
Julie A. Bastarache
WKWolfgang Kuebler
Wolfgang Kuebler
GDGregory P. Downey
Gregory P. Downey
GMGutavo Matute-Bello
Gutavo Matute-Bello
Advancements in methods, technology, and our understanding of the pathobiology of lung injury have created the need to update the definition of experimental acute lung injury (ALI). We queried 50 participants with expertise in ALI and acute respiratory distress syndrome using a Delphi method composed of a series of electronic surveys and a virtual workshop. We propose that ALI presents as a “multidimensional entity” characterized by four “domains” that reflect the key pathophysiologic features and underlying biology of human acute respiratory distress syndrome. These domains are 1) histological evidence of tissue injury, 2) alteration of the alveolar–capillary barrier, 3) presence of an inflammatory response, and 4) physiologic dysfunction. For each domain, we present “relevant measurements,” defined as those proposed by at least 30% of respondents. We propose that experimental ALI encompasses a continuum of models ranging from those focusing on gaining specific mechanistic insights to those primarily concerned with preclinical testing of novel therapeutics or interventions. We suggest that mechanistic studies may justifiably focus on a single domain of lung injury, but models must document alterations of at least three of the four domains to qualify as “experimental ALI.” Finally, we propose that a time criterion defining “acute” in ALI remains relevant, but the actual time may vary based on the specific model and the aspect of injury being modeled. The continuum concept of ALI increases the flexibility and applicability of the definition to multiple models while increasing the likelihood of translating preclinical findings to critically ill patients.

1 September 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HAH. Luke Anderson
H. Luke Anderson
IBIgor E. Brodsky
Igor E. Brodsky
NMNilam S. Mangalmurti
Nilam S. Mangalmurti
The field of red cell biology is undergoing a quiet revolution. Long assumed to be inert oxygen carriers, RBCs are emerging as important modulators of the innate immune response. Erythrocytes bind and scavenge chemokines, nucleic acids, and pathogens in circulation. Depending on the conditions of the microenvironment, erythrocytes may either promote immune activation or maintain immune quiescence. We examine erythrocyte immune function through a comparative and evolutionary lens, as this framework may offer perspective into newly recognized roles of human RBCs. Next, we review the known immune roles of human RBCs and discuss their activity in the context of sepsis where erythrocyte function may prove important to disease pathogenesis. Given the limited success of immunomodulatory therapies in treating inflammatory diseases, we propose that the immunologic function of RBCs provides an understudied and potentially rich area of research that may yield novel insights into mechanisms of immune regulation.

20 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
LLL. K. Metthew Lam
L. K. Metthew Lam
SMSophia Murphy
Sophia Murphy
DKDimitra Kokkinaki
Dimitra Kokkinaki
AVAlessandro Venosa
Alessandro Venosa
SSScott Sherrill-Mix
Scott Sherrill-Mix
NMNilam S. Mangalmurti
Nilam S. Mangalmurti
Red blood cells detect and bind cell-free nucleic acids, contributing to anemia and immune cell activation during acute inflammation.

15 February 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MHMeghan J. Hotz
Meghan J. Hotz
DQDanielle Qing
Danielle Qing
MSMichael G. S. Shashaty
Michael G. S. Shashaty
PZPeggy Zhang
Peggy Zhang
HFHilary Faust
Hilary Faust
NMNilam S. Mangalmurti
Nilam S. Mangalmurti
Rationale: Potentially hazardous CpG-containing cell-free mitochondrial DNA (cf-mtDNA) is routinely released into the circulation and is associated with morbidity and mortality in critically ill patients. How the body avoids inappropriate innate immune activation by cf-mtDNA remains unknown. Because red blood cells (RBCs) modulate innate immune responses by scavenging chemokines, we hypothesized that RBCs may attenuate CpG-induced lung inflammation through direct scavenging of CpG-containing DNA. Objectives: To determine the mechanisms of CpG-DNA binding to RBCs and the effects of RBC-mediated DNA scavenging on lung inflammation. Methods: mtDNA on murine RBCs was measured under basal conditions and after systemic inflammation. mtDNA content on human RBCs from healthy control subjects and trauma patients was measured. Toll-like receptor 9 (TLR9) expression on RBCs and TLR9-dependent binding of CpG-DNA to RBCs were determined. A murine model of RBC transfusion after CpG-DNA–induced lung injury was used to investigate the role of RBC-mediated DNA scavenging in mitigating lung injury in vivo. Measurements and Main Results: Under basal conditions, RBCs bind CpG-DNA. The plasma-to-RBC mtDNA ratio is low in naive mice and in healthy volunteers but increases after systemic inflammation, demonstrating that the majority of cf-mtDNA is RBC-bound under homeostatic conditions and that the unbound fraction increases during inflammation. RBCs express TLR9 and bind CpG-DNA through TLR9. Loss of TLR9-dependent RBC-mediated CpG-DNA scavenging increased lung injury in vivo. Conclusions: RBCs homeostatically bind mtDNA, and RBC-mediated DNA scavenging is essential in mitigating lung injury after CpG-DNA. Our data suggest a role for RBCs in regulating lung inflammation during disease states where cf-mtDNA is elevated, such as sepsis and trauma.

15 November 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JCJason D. Christie
Jason D. Christie
CSChirag V. Shah
Chirag V. Shah
SKSteven M. Kawut
Steven M. Kawut
NMNilam Mangalmurti
Nilam Mangalmurti
DLDavid J. Lederer
David J. Lederer
LWLorraine B. Ware
Lorraine B. Ware
Rationale: The receptor for advanced glycation end products (RAGE) is an important marker of lung epithelial injury and may be associated with impaired alveolar fluid clearance. We hypothesized that patients with primary graft dysfunction (PGD) after lung transplantation would have higher RAGE levels in plasma than patients without PGD. Objectives: To test the association of soluble RAGE (sRAGE) levels with PGD in a prospective, multicenter cohort study. Methods: We measured plasma levels of sRAGE at 6 and 24 hours after allograft reperfusion in 317 lung transplant recipients at seven centers. The primary outcome was grade 3 PGD (PaO2/Fi O2 < 200 with alveolar infiltrates) within the first 72 hours after transplantation. Measurements and Main Results: Patients who developed PGD had higher levels of sRAGE than patients without PGD at both 6 hours (median 9.3 ng/ml vs. 7.5 ng/ml, respectively; P = 0.028) and at 24 hours post-transplantation (median 4.3 ng/ml vs. 1.9 ng/ml, respectively; P < 0.001). Multivariable logistic regression analyses indicated that the relationship between levels of sRAGE and PGD was attenuated by elevated right heart pressures and by the use of cardiopulmonary bypass. Median sRAGE levels were higher in subjects with cardiopulmonary bypass at both 6 hours (P = 0.003) and 24 hours (P < 0.001). sRAGE levels at 6 hours were significantly associated with intraoperative red cell transfusion (Spearman's ρ = 0.39, P = 0.002 in those with PGD), and in multivariable linear regression analyses this association was independent of confounding variables (P = 0.02). Conclusions: Elevated plasma levels of sRAGE are associated with PGD after lung transplantation. Furthermore, plasma sRAGE levels are associated with blood product transfusion and use of cardiopulmonary bypass.